Table 3. Clinicopathologic characteristics and outcomes of crizotinib therapy in 2 patients with rare ALK fusion types detected by capture-based NGS.

Fusion type	Sex	Age (years)	Histology	Surgical history	Clinical stage before crizotinib therapy	ag	Crizotinib therapy
							Timing	Overall response	Status	PFS (months)
FAM179A-ALK	Female	36	Adenocar- cinoma	None	T4N2M1b IV	None	First-line	PR	Not PD	12.06
COL25A1-ALK	Male	58	Adenocar-cinoma	Resected P-T2aN0M0 Poorly differ- entiated	r-T0N0M1b IV	None	First-line	PR	PD	6.28

NGS, next-generation sequencing; PD, progressive disease; PFS, progression-free survival; PR, partial response.